Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
PaperCitations, authors & open-access status
Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 608 citations, 2017 year and green oa status.
608
Citations
2017
Year
green
OA Status